Combination treatment before surgery for stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combined with chemotherapy before surgery for stomach cancer that has spread to nearby areas. It aims to shrink the tumor to make surgery more successful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach cancer or cancer where the stomach meets the esophagus.
- Your cancer can be removed with surgery, but it has spread to nearby lymph nodes or other limited areas.
- Your cancer is HER2-negative or low, and has a PD-L1 CPS score of 1 or higher.
- You are between 18 and 75 years old.
- You have not had chemotherapy or other treatments for advanced stomach cancer before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests a new combination of three drugs for stomach cancer that has progressed after initial immunotherapy. It aims to see if this combo can shrink tumors or slow cancer growth, potentially offering a new option for patients like you.
This trial tests a combination of four drugs given before surgery to shrink stomach cancer and improve the chances of successful removal. It is for people with locally advanced stomach or gastroesophageal junction cancer that has not been treated yet.
This trial tests a combination of new drugs given before surgery for stomach or gastroesophageal junction cancer. The goal is to see if it can shrink tumors and improve outcomes for patients whose cancer has certain markers.
This trial tests a combination of four treatments (two investigational drugs, a targeted therapy, and chemotherapy) as a first-line option for people with advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination can help shrink or control the cancer.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.